Innexus = 1st product Tues.

It sounds like InNexus, the biotech drug that has most of its operations based on the Mayo Clinic Scottsdale campus and has toyed with the idea putting a facility in Rochester, is unveiling its first product Tuesday.

If this hits big, I wonder if that will make the Rochester facility more likely? We'll see I guess.

Here's some from a piece in the Arizona Republic about this:

InNexus Biotechnology Inc., a young Scottsdale drug development company, will debut its first product Tuesday at a major pharmaceutical industry conference in Boston.

The new drug, DXL 625, may sound like the name of a luxury car, but is actually an antibody that targets CD20-positive non-Hodgkin's lymphoma, a form of cancer.

InNexus chief executive Jeff Morhet will announce the new treatment at the IBC Drug Discovery & Development of Innovative Therapeutics World Conference, an annual meeting that features new drugs.

During the past nine months, InNexus has taken the drug from an idea to pre-clinical testing, Morhet said.

"It's our coming out party. Does that make us debutantes?" joked Morhet, whose Vancouver, B.C. firm bases most of its drug research and management at Mayo Clinic in Scottsdale.

After several years of gearing up its finances, human capital and scientific inquiries, the company bows before the pharmaceutical business elite Tuesday at a scientific conference in Boston.

"We picked this meeting because it has the best scientific credibility across the industry," said Morhet. Credibility is crucial to his company's business plan, which is to develop early stage drugs that can be sold to major drug companies for human testing and public introduction. All InNexus projects involve making antibody treatments more robust. Cancer is the main focus.

"